Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Compare volatility and returns in retirement index funds to strike a balance between potential growth and risk control for sustainable withdrawals.
24,638 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
SpaceX, Rocket Lab, and AST SpaceMobile retreat as a China rocket milestone and an oil price spike pressure space-sto...
Warren Buffett resurfaces on CNBC as Berkshire Hathaway shares retreat, highlighting leadership transition questions ...
Oklo stock surged as investors weighed its plans for advanced reactors against the fast-moving AI data-center boom. T...
A U.S. freeskier who once faced a public jab from the president miles ahead in the Olympic season posts a strong qual...
AMH reports solid 2025 results as it navigates an overbuilt rental market, with revenue gains driven by disciplined a...
A high-stakes clash between AI safety and national security is unfolding. Anthropic won’t lift safeguards even as the...
In a market where homes linger and prices shift, using lowball offers can put you in the driver's seat. Learn how to ...
JPMorgan CEO Jamie Dimon dismissed Donald Trump’s $5 billion debanking lawsuit as meritless, but said he understands ...
In a high-stakes New Mexico trial, Mark Zuckerberg argues that Facebook and Instagram are not designed to be addictiv...
A high-profile critique of a blockbuster series shines a light on how media can nudge spending habits. This article b...
Two high-profile crypto conferences in Dubai were canceled as regional tensions intensified. This article dives into ...